Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

 Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Shots:

  • Mundipharma to get exclusive rights to market and distribute Biosolution’s CartiLife in South Korea. In May 2016, the companies signed commercialization agreement for allogeneic keratinocyte cell therapy product, KeraHeal-Allo and is the second agreement signed presently
  • The focus of the agreement is to include Biosolution’s CartiLife in the Mundipharma’s portfolio of orthopedic care
  • CartiLife is a fourth-generation autologous cartilage-derived chondrocyte cell therapy targeted to treat cartilage defects (ICRS grade 3 or 4) involved in reduction of host-immune rejection due to its autologous nature with restoration of hyaline cartilage causing less invasion surgery

Click here to read full press release/ article | Ref: PRNewswire | Image: Evaluate

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post